Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALDX NASDAQ:ALT NASDAQ:FDMT NASDAQ:KLRS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$4.96-2.6%$5.37$1.14▼$7.20$304.87M0.8774,038 shs796,478 shsALTAltimmune$3.63+1.1%$3.81$2.90▼$11.16$316.84M0.182.38 million shs1.92 million shsFDMT4D Molecular Therapeutics$6.69-1.6%$5.75$2.23▼$17.41$317.58M2.86550,496 shs465,082 shsKLRSKalaris Therapeutics$5.01+35.0%$3.06$2.14▼$24.15$69.39M0.37692,784 shs417,861 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics-5.57%-10.70%-5.57%+64.72%-15.59%ALTAltimmune-1.37%-3.23%-1.10%-47.90%-54.44%FDMT4D Molecular Therapeutics-0.15%-2.44%-6.34%+63.86%-58.15%KLRSKalaris Therapeutics-4.63%-20.04%+50.81%+44.92%+370,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$4.96-2.6%$5.37$1.14▼$7.20$304.87M0.8774,038 shs796,478 shsALTAltimmune$3.63+1.1%$3.81$2.90▼$11.16$316.84M0.182.38 million shs1.92 million shsFDMT4D Molecular Therapeutics$6.69-1.6%$5.75$2.23▼$17.41$317.58M2.86550,496 shs465,082 shsKLRSKalaris Therapeutics$5.01+35.0%$3.06$2.14▼$24.15$69.39M0.37692,784 shs417,861 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics-5.57%-10.70%-5.57%+64.72%-15.59%ALTAltimmune-1.37%-3.23%-1.10%-47.90%-54.44%FDMT4D Molecular Therapeutics-0.15%-2.44%-6.34%+63.86%-58.15%KLRSKalaris Therapeutics-4.63%-20.04%+50.81%+44.92%+370,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALDXAldeyra Therapeutics 2.67Moderate Buy$9.5091.53% UpsideALTAltimmune 2.57Moderate Buy$17.40379.34% UpsideFDMT4D Molecular Therapeutics 2.64Moderate Buy$30.40354.41% UpsideKLRSKalaris Therapeutics 3.00Buy$3.00-40.12% DownsideCurrent Analyst Ratings BreakdownLatest KLRS, FDMT, ALT, and ALDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/13/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating9/2/2025KLRSKalaris TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy8/30/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating8/14/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating8/13/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.008/13/2025ALTAltimmuneUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$26.00 ➝ $24.008/13/2025ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $18.008/12/2025FDMT4D Molecular TherapeuticsRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$44.00 ➝ $38.008/12/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.008/8/2025ALDXAldeyra TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/1/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALDXAldeyra TherapeuticsN/AN/AN/AN/A$1.19 per shareN/AALTAltimmune$20K16,018.65N/AN/A$1.74 per share2.09FDMT4D Molecular Therapeutics$33K9,467.77N/AN/A$11.05 per share0.61KLRSKalaris TherapeuticsN/AN/AN/AN/A$22.47 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALDXAldeyra Therapeutics-$55.85M-$0.85N/AN/AN/AN/A-73.63%-50.61%11/6/2025 (Estimated)ALTAltimmune-$95.06M-$1.18N/AN/AN/A-438,730.03%-62.63%-55.29%11/11/2025 (Estimated)FDMT4D Molecular Therapeutics-$160.87M-$3.53N/AN/AN/A-594,375.81%-40.15%-36.43%11/12/2025 (Estimated)KLRSKalaris Therapeutics-$58.77MN/A0.00∞N/AN/A-81.02%-65.15%N/ALatest KLRS, FDMT, ALT, and ALDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025KLRSKalaris Therapeutics-$0.51-$0.61-$0.10-$0.61N/AN/A8/12/2025Q2 2025ALTAltimmune-$0.32-$0.27+$0.05-$0.27$0.00 million$0.01 million8/11/2025Q2 2025FDMT4D Molecular Therapeutics-$0.88-$0.98-$0.10-$0.98$0.52 million$0.01 million8/7/2025Q2 2025ALDXAldeyra Therapeutics-$0.21-$0.16+$0.05-$0.16$1.08 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALDXAldeyra TherapeuticsN/AN/AN/AN/AN/AALTAltimmuneN/AN/AN/AN/AN/AFDMT4D Molecular TherapeuticsN/AN/AN/AN/AN/AKLRSKalaris TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALDXAldeyra TherapeuticsN/A2.862.86ALTAltimmune0.0920.4420.44FDMT4D Molecular TherapeuticsN/A8.758.75KLRSKalaris TherapeuticsN/A11.9811.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALDXAldeyra Therapeutics59.71%ALTAltimmune78.05%FDMT4D Molecular Therapeutics99.27%KLRSKalaris Therapeutics66.05%Insider OwnershipCompanyInsider OwnershipALDXAldeyra Therapeutics8.50%ALTAltimmune4.40%FDMT4D Molecular Therapeutics9.60%KLRSKalaris Therapeutics74.99%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALDXAldeyra Therapeutics1059.90 million54.81 millionOptionableALTAltimmune5088.26 million84.37 millionOptionableFDMT4D Molecular Therapeutics12046.70 million42.22 millionOptionableKLRSKalaris Therapeutics11018.70 million4.68 millionN/AKLRS, FDMT, ALT, and ALDX HeadlinesRecent News About These CompaniesUPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular DegenerationSeptember 15 at 3:26 PM | globenewswire.comKalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular DegenerationSeptember 15 at 8:00 AM | globenewswire.comKalaris Therapeutics (NASDAQ:KLRS) Trading 0.9% Higher - Still a Buy?September 12, 2025 | marketbeat.comKalaris Therapeutics Inc. (KLRS) Upgraded to Buy: Here's What You Should KnowSeptember 1, 2025 | zacks.comKalaris Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 13, 2025 | globenewswire.comBernstein Liebhard LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of AlloVir, Inc. SecuritiesJune 5, 2025 | globenewswire.comKalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity ConferenceJune 2, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 20252 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025Medtronic: The Opportunity Gets Healthier for Income InvestorsBy Thomas Hughes | August 19, 2025Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksBy Thomas Hughes | August 19, 2025Palo Alto Networks Uptrend Confirmed! New Highs Set by Year’s EndBy Thomas Hughes | August 19, 2025KLRS, FDMT, ALT, and ALDX Company DescriptionsAldeyra Therapeutics NASDAQ:ALDX$4.96 -0.13 (-2.55%) Closing price 04:00 PM EasternExtended Trading$5.03 +0.07 (+1.31%) As of 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.Altimmune NASDAQ:ALT$3.63 +0.04 (+1.11%) Closing price 04:00 PM EasternExtended Trading$3.62 -0.01 (-0.28%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.4D Molecular Therapeutics NASDAQ:FDMT$6.69 -0.11 (-1.62%) Closing price 04:00 PM EasternExtended Trading$6.72 +0.03 (+0.45%) As of 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.Kalaris Therapeutics NASDAQ:KLRS$5.01 +1.30 (+35.04%) As of 04:00 PM EasternAllovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
